Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence

15. Mai 2026 aktualisiert von: Feifei Huang

The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. The study will also evaluate the feasibility, acceptability, and preliminary effectiveness of the ADAPT program.

The main research questions are as follows:

  • Is the ADAPT intervention program feasible and acceptable for lung cancer patients and their spouse caregivers?
  • Compared with usual care, can the ADAPT intervention program preliminarily reduce FCR levels in both patients and their spouse caregivers? Can the program improve coping styles, illness perceptions, family functioning, and intimate relationships among both patients and their spouse caregivers? Can the program enhance psychological flexibility and quality of life (QOL) in both patients and their spouse caregivers? Researchers will compare the ADAPT intervention program with usual care to evaluate its preliminary effectiveness in reducing FCR among lung cancer patients and their spouse caregivers.

Participants will:

  • Receive the ADAPT intervention twice during each radiotherapy and/or chemotherapy cycle, for a total of three treatment cycles (approximately 3 months);
  • Complete questionnaires at baseline (before the intervention), immediately after the intervention, and one month post-intervention;
  • Report outcomes including FCR severity, FCR triggers, psychological flexibility, illness perception, dyadic coping, family functioning, intimacy, and quality of life (QOL).

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

72

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Feifei Huang, Ph. D
  • Telefonnummer: +86 13763869099
  • E-Mail: pt860315@163.com

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria

Patients:

  • Diagnosis of primary lung cancer confirmed by pathological examination.
  • Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China).
  • Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and/or chemotherapy treatment
  • Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR.
  • Eastern Cooperative Oncology Group (ECOG) ≤2.
  • Aware of their diagnosis and willing to participate voluntarily.
  • Normal cognitive function (Montreal Cognitive Assessment [MoCA] score ≥ 26), alert and conscious, and able and willing to communicate their thoughts.

Spouse Caregivers:

  • Identified by the patient as the primary caregiver, providing ≥ 50% of care in the past 2 weeks.
  • Legally married to the patient.
  • Age ≥ 22 years for men and ≥ 20 years for women.
  • Normal cognitive function (MoCA score ≥ 26), no diagnosed mental disorders, able to communicate effectively, and willing to share their thoughts.

Exclusion Criteria

Patients:

  • Diagnosed mental disorders or currently receiving psychiatric treatment.
  • Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease.
  • Concurrent malignant tumors in other organs.
  • Severe complications (e.g., chest pain and/or dyspnea due to pleural tumor invasion).
  • Spouse caregiver unwilling to participate.
  • History of upper limb fractures or surgery resulting in impaired hand function.
  • Participation in other similar psychological interventions.

Spouse Caregivers:

  • Presence of serious comorbid conditions (e.g., respiratory failure, malignant tumors, or other critical illnesses).
  • Patient unwilling to participate.
  • Participation in other research studies.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Interventionsgruppe
Sonstiges: Dyadic Acceptance and Commitment Therapy (ACT) for lung cancer patients and their spouse caregivers addressing FCR and routine care

In addition to routine care provided to the control group, the ACT intervention will be delivered by researchers who have completed formal training in Acceptance and Commitment Therapy (ACT). The intervention will be conducted in a quiet and comfortable demonstration room within the department.

The intervention will be delivered in a face-to-face, couple-based format. It will consist of six sessions, with two sessions per treatment cycle, each lasting 35-75 minutes, over a total of three treatment cycles.

The intervention will incorporate techniques such as metaphor-based exercises, mindful breathing, body scan, the T-puzzle, and the Chinese finger trap.

The preliminary structure is as follows: six fixed in-person sessions (Sessions 1-6), supplemented by online homework assignments completed between sessions.
Aktiver Komparator: Kontrollgruppe
Sonstiges: routine care

① Health education:

  1. Disease knowledge education

  2. Nutrition and hygiene education

    • Follow-up management and symptom monitoring: Conduct a telephone follow-up within one month after the patient is discharged from the hospital to ensure timely monitoring of the patient's physical condition.

      • Home rehabilitation management: Provide nutritional counseling services for the patient and spouse caregiver, guide home-based dietary adjustments, and maintain good nutritional status and immunity. Encourage the patient and spouse caregiver to communicate promptly with the medical team when experiencing uncomfortable symptoms, thereby speeding up recovery and improving rehabilitation outcomes.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline in fear of cancer recurrence severity of lung cancer patients-The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in fear of cancer recurrence severity of spouse caregivers-Fear of Cancer Recurrence Inventory Short Form-Caregiver Version (FCRI-SF-C)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The scale consists of 9 items, each rated from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 36, where 0 indicates no fear of cancer recurrence and 36 indicates the highest possible fear. A score of 13 or higher is defined as subclinical fear of cancer recurrence.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recruitment Rate: Percentage of Eligible Participants Who Successfully Enroll in the Study Out of All Potentially Eligible Participants Meeting Inclusion/Exclusion Criteria
Zeitfenster: Post-intervention (3 months)
Recruitment rate is calculated as (number of eligible participants who successfully enroll in the study / total number of potentially eligible participants meeting all inclusion and none of the exclusion criteria) × 100%. The rate ranges from 0% to 100%, with a higher rate indicating better recruitment efficiency.
Post-intervention (3 months)
Consent Compliance Rate: Percentage of Participants Who Sign Informed Consent Among Those Who Meet Inclusion Criteria
Zeitfenster: Post-intervention (3 months)
Consent compliance rate is calculated as (number of participants who sign the informed consent form / total number of participants who meet the predefined inclusion criteria) × 100%. The rate ranges from 0% to 100%.
Post-intervention (3 months)
Participation Rate: Percentage of Randomized Participants Who Completed All Intervention Sessions
Zeitfenster: Post-intervention (3 months)
Participation rate is calculated as (number of participants who completed all intervention sessions / total number of participants randomized) × 100%. The rate ranges from 0% to 100%.
Post-intervention (3 months)
Withdrawal Rate: Percentage of Initially Enrolled Participants Who Voluntarily Withdraw or Are Lost to Follow-Up
Zeitfenster: Post-intervention (3 months)
Withdrawal rate is calculated as (number of participants who voluntarily withdraw from the study or are lost to follow-up after enrollment / total number of participants initially enrolled) × 100%. The rate ranges from 0% to 100%.
Post-intervention (3 months)
Number of Participants with Study-Related Adverse Events as Assessed by CTCAE v4.0
Zeitfenster: Intervene in the whole process (3 months)
The study uses a self-developed Adverse Event Form to document study-related adverse events (AEs) occurring during the study period. The incidence rate is calculated as (number of participants experiencing at least one study-related AE / total number of enrolled participants) × 100%. Severity grading follows the CTCAE v4.0.
Intervene in the whole process (3 months)
Satisfaction with the Intervention Program as Assessed by Qualitative Interviews
Zeitfenster: Post-intervention (3 months)
Semi-structured interviews are conducted by the investigator using a final interview guide developed through group brainstorming and revised by a nursing professor experienced in qualitative research. Sampling continues until no new themes emerge and meaning saturation is achieved. Thematic analysis is used to identify satisfaction-related patterns, and findings are reported with representative quotes. No predefined numeric threshold is applied.
Post-intervention (3 months)
Change from baseline in fear of cancer recurrence triggering factors-The Fear of Cancer Recurrence Inventory-Triggering factors (FCRI-T)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
This 8-item dimension assesses how often daily triggers elicit fear of cancer recurrence. Each item is scored from 0 to 4. Zero is equivalent to "never" and 4 indicates "always". Total scores range from 0 to 32, where 0 indicates that none of the factors trigger fear and 32 indicates that all factors always trigger fear.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in psychological flexibility-Comprehensive Assessment of ACT Processes (CompACT)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The CompACT contains 22 items, each scored from 0 to 6. Zero is equivalent to "never" and 6 indicates "always". After reverse-scoring the values and committed action domain (plus four items of the mindfulness and self-as-context domain), total scores range from 0 to 132, where 0 indicates the lowest possible psychological flexibility and 132 indicates the highest possible psychological flexibility.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in illness perception-Brief Illness Perception Questionnaire (B-IPQ)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The B-IPQ includes 8 items, each scored from 0 to 10. Zero is equivalent to "no perception of that aspect" and 10 indicates "extreme perception of that aspect". Total scores range from 0 to 80, where 0 indicates a very benign illness perception and 80 indicates the most threatening illness perception possible. The ninth open-ended item asks participants to list the three most important causal factors.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in dyadic coping-Dyadic Coping Inventory (DCI)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The DCI consists of 37 items, each rated from 1 to 5. One is equivalent to "very rarely" and 5 indicates "very frequently". Total scores range from 35 to 75, where 35 indicates the lowest possible dyadic coping competence and 75 indicates the highest possible dyadic coping competence.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in intimate relationship-Unidimensional Relationship Closeness Scale (URCS)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
This 11-item scale uses a 5-point scale from 1 to 5. 1 is equivalent to "strongly disagree" and 5 indicates "strongly agree". The mean of all item scores is calculated, ranging from 1 to 5, where 1 indicates the lowest perceived closeness and 5 indicates the highest perceived closeness.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in family care-Family Adaptation, Partnership, Growth, Affection, Resolve index Questionnaire (Family APGAR Questionnaire)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The Family APGAR has 5 items, each scored from 0 to 2. Zero is equivalent to "hardly ever" and 2 indicates "almost always". Total scores range from 0 to 10, where 0 indicates the poorest family function and 10 indicates the best family function. Scores of 7-10 indicate good family function, 4-6 moderate dysfunction, and 0-3 severe dysfunction.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of lung cancer patients-Functional Assessment of Cancer Therapy (FACT-L V4.0)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The FACT-L V4.0 consists of 36 items. Each item is scored from 0 to 4. Zero is equivalent to "not at all" and 4 indicates "very much". Positively worded items are scored 0-4; reverse-worded items are scored 4-0. The total score is the sum of five dimension scores (physical, social/family, emotional, functional, and lung-specific), ranging from 0 to 144, where 0 indicates the poorest possible quality of life and 144 indicates the best possible quality of life.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
Change from baseline in quality of life of spouse caregivers-The 12-item short from healthy survey (SF-12)
Zeitfenster: Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)
The SF-12 includes 12 items covering eight dimensions. Items 1,8,9,10 are reverse-scored. Standardized scores for the PCS and MCS each range from 0 to 100, where 0 indicates the worst possible quality of life and 100 indicates the best possible quality of life.
Baseline, after the third intervention (1.5 months), post-intervention (3 months), 1 month after intervention (4 months)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Feifei Huang

Ermittler

  • Studienleiter: Feifei Huang, Ph. D, Fujian Medical University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Mai 2026

Primärer Abschluss (Geschätzt)

30. Juni 2027

Studienabschluss (Geschätzt)

30. Juni 2027

Studienanmeldedaten

Zuerst eingereicht

4. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Mai 2026

Zuerst gepostet (Tatsächlich)

14. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • Ethical Review No. 2 (2026)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

The datasets are not publicly available due privacy reasons but are available from the director upon reasonable request.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Lungentumoren

Klinische Studien zur routine care

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Philippines

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren